Interventional cardiologist at UAB and VA
Resume:
CURRICULUM VITAE
NAME: Massoud A. Leesar, M.D.
ADDRESS: *** **** ****** *****, ***: 920
Birmingham, AL 34294
CITIZENSHIP USA
E-MAIL *******@***.***
TELEPHONE: 205-***-****
*/*/****-******* **ofessor of Medicine
Baker-Dean Endowed Professor in Interventional
Cardiology
Interventional Cardiologist
7/1/2009- 4/2012 Director, Cardiac Cath Lab, Westchester Medical Center, University of Cincinnati
7/1/2007-4/30/2012 Professor of Medicine (tenured) Associate Chief, Division of Cardiology
Director, Cardiac and Vascular Invasive Services,
University of Cincinnati and VA Medical Center
7/1/2004-6/30/2007 Professor of Medicine (tenured) Director of Cardiac Catheterization and interventional Cardiology, University of Louisville and VA Medical center 1999-2004 Associate Professor of Medicine (tenured) Director of Cardiac Catheterization and interventional Cardiology, University of Louisville and VA Medical Center 1994-1999 Assistant Professor of Medicine (tenured track) Director of Cardiac Catheterization and interventional Cardiology, University of Louisville and VA Medical Center POSTGRADUATE TRAINING
1993-1994 Fellowship in Interventional Cardiology
University of Louisville School of Medicine
Louisville, Kentucky
1992-1993 Research Fellowship in Interventional Cardiology University of Louisville School of Medicine
Louisville, Kentucky
2
1990-1992 Fellowship in Cardiology
Detroit Medical Center
Wayne State University
Detroit, Michigan
1989-1990 Fellowship in Critical Care Medicine
University of Cincinnati Hospital
Cincinnati, Ohio
1987-1989 Residency in Internal Medicine
Yale-Waterbury Program
1986-1987 Residency in Internal Medicine
University of Toronto
Toronto, Canada
1985-1986 Research Fellow
Montreal General Hospital
Montreal, Quebec, Canada
1981 M.D, Mashad University, Iran
MEDICAL LICENSURE
Connecticut medical license, 1987
Michigan medical license, 1990
Kentucky medical license, 1992
Ohio Sate Board 2006
CERTIFICATION
American Board of Internal Medicine, certified indefinitely: Sept. 1989. American Board of Cardiology, certified Nov. 2005: I am meeting the ABIM MOC requirement through ACC collaborative maintenance pathway.
American Board of Interventional Cardiology, certified Nov. 2013 ECFMG, certified May, 1987
Medical Council of Canada Evaluating Exam certified PROFESSIONAL AND SCIENTIFIC SOCIETIES
Fellow, American College of Cardiology
3
Fellow, Society of Coronary Angiography and Intervention Member, American Medical Association
Chair-Intravascular Imaging: Society of Cardio-Oncology EDITORIAL BOARD
JACC Cardiovascular Intervention
Catheterization and Cardiovascular Interventions
Journal of Society of Coronary Angiography and Interventions Cardiovascular Revascularization Medicine
Consulting Editor : Journal of Cardiovascular aging REVIEWER
AHA abstract session
TCT abstract session
ACC abstract session
CRT abstract reviewer
Circulation
Coronary Artery Disease
Journal of American College of Cardiology
JACC-Intervention
Circulation-Intervention
Circulation Research
Catheterization and cardiovascular interventions
American Board of Internal Medicine-Interventional Cardiology. Journal of Interventional Cardiology
AWARDS
1994 University of Louisville, Department of
Medicine Research Award.
2007 Fellows teaching award, University of Louisville 2010 Fellows teaching award, University of Cincinnati 2012 Fellows teaching award, University of Cincinnati 2010 Best Doctor Award
2011 Best Doctor Award
2012-2020 Best Doctor Award
4
2013 Baker-Dean Endowed Professorship In Interventional Cardiology
2016-2020 Castle Connolly best doctor award
2018 UAB Medicine Award
2019 Department of veteran affairs: 20 Years Service Award 2020 UAB Medicine Award
2021 CRT Meeting: Faculty and abstract reviewer committee HOSPOTAL APPIONTMENTS
University of Alabama-Birmingham
University of Cincinnati
University of Louisville Hospital
VA Medical Center
5
Research
A. Investigator-initiated research studies
1. TRIP-MI2: PAR1 Pepducin-Based Prevention of Arterial Thrombosis and Myocardial Infarction : A novel therapeutic strategy in patients with ACS. FOA: PAR-18-407
Application: UG3 HL-141726-01A1
Funding agency: NIH,
Dates: 04-01-2019 – 03-31-2025, approved at the council meeting; pending funding $5.7 million Project/Performance Sites: University of Alabama- Birmingham and 5 other sites Consortium PI: Massoud A. Leesar, MD
2. The role of IVUS on stent optimization with the novel HD-IVUS system. The first US study with the novel 60 MHZ IVUS system
Role PI
Dates: 2019-2022
Funding agency: ACIST
The first HD-IVUS trial in US
3. Crushed ticagrelor vs. eptifibatide bolus in patients with unstable angina. Role : PI
Dates: 2019-2021
Agency: Astrazeneca
The manuscript was submitted to JAMA Cardiology
4. Cerebral Hemodynamics and Neurocognition in Severe Aortic Valve Disease Agency: NIH/NINDS :R21NS096972-01A1
Role: Co-PI
Dates: 2018-2021
5. HARP: NYU Women’s Heart Attack Research Program (NYU HARP) Agency: AHA
Role; Co-PI
Dates 2018-2021
6. Pending Grant
Agency: NIH (R34)
The role of crushed ticagrelor vs. eptifibatide bolus in patients with NSTE-ACS: a randomized clinical trial
Status: under review
6
B: Multicenter research studies
1. Tendyne : SUMMIT study: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation 2. Ilumien IV: OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI 3. SHIELD: Safety and Effectiveness of Remote Ischemc Conditioning with the Autoric Prior to Elective PCI Study (SHIELD STUDY)
4. ECLIPSE: Comparisons of CSI vs. rotational atherectomy in patients with calcified lesions 5. COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional MR (The COAPT Trial): A Clinical Evaluation of the Safety and Effectiveness of the MitraClip® System for the Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects
6. Absorb: A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions 7. EVOLVE: EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGYTM 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGYTM Stent System) for the Treatment of Subjects with Atherosclerotic Lesion(s) 7
C. Completed investigator-originated Research Projects: 1. Effect of enalaprilat induced precoditioning in patients undergoing coronary angioplasty
(2002- 2007). JACC 2007 ;49:1607-10. PMID: 17433950 Sponsor : NIH, R01-HL 68088
Role: Co-PI
2. CORAL Study: Site PI, 2005-2010
Cardiovascular Outcomes in Renal Atherosclerotic Lesions Sponsor: NHLBI
Role: Director of IVUS Core Lab for the CORAL IVUS substudy and site PI; Application ID# 1 R01 DK083487-01
(NIDDK: Application ID# 1 R01
3. FAME Study
Comparison of fractional flow reserve-guided vs. conventional PCI in patients with multi- vessel PCI. N Engl J Med. 2009; 360:213-24. J Am Coll Cardiol. 2010 ;55:2816-21. Agency: RADI
Role: Organizer and Site PI
4. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. JACC 2007 ;49:2398-407
Sponsor: Nuvelo, Inc.
Role: site PI
5. Left Ventricular torsional hysteresis: A global parameter for diastolic function. The overall goal of the project is to assess the correlations between left ventricular filling pressures measured by Millard catheter in the cath lab with cardiac MRI. Sponsor: NHLBI
Role: Co-PI
Dates: 2010-2015
6. Proximal Optimization Technique Guided by Intravascular Ultrasound on Stent Expansion, Stent Symmetry Index, and Side-Branch Hemodynamics in Patients With Coronary Bifurcation Lesions: Role PI
Sponsor: UAB
Dates: 2016-2017
7. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
Role: PI
Sponsor: AstraZeneca
Dates: 2015-2017
8. The effect of crushed ticagrelor vs. eptifibatide bolus+ clopidogrel in patients with unstable angina
Role: PI
Sponsor: AstraZeneca
8
Dates: 2016-2019
9. A novel fluoroscopic-guided technique with micropuncture needle for the common femoral artery access.
Role: PI
Sponsor: UAB
Dates: 2018-2019
9
INVITED SPEAKER IN SCIENTIFIC SESSIONS
SCAI 28th annual scientific sessions, Ponte Vedra Beach, FL (May 2005) Title: FFR guided vs. conventional multivesel PCI-30 months outcome Transcatheter Therapy (TCT), Washington DC, Oct 16-21 (2005) Date: Sun Oct 16
Event Title: IVUS and Physiologic Lesion Assessment: Applications in the DES Era Section Title: Session II. A Problem Oriented Approach to IVUS and Physiologic Guidance Lecture Title: IVUS and FFR/CFR in left main disease I: When to intervene in the ambiguous or borderline lesion
Role: Lecturer
Room: 150AB
Location: Washington Convention Center
Date: Sun Oct 16
Event Title: IVUS and Physiologic Lesion Assessment: Applications in the DES Era Section Title: Session II. A Problem Oriented Approach to IVUS and Physiologic Guidance (with case reviews)
Lecture Title: Roundtable audience Q&A
Role: Discussant
Room: 150AB
Location: Washington Convention Center
Date: Mon Oct 17
Time: 02:00 PM-04:00 PM
Event Title: Masters Course in Complex Coronary and Peripheral Intervention - Monday Section Title: LIVE CASE - SESSION 3, Peripheral Cases Role: Live Case Discussant
Room: Masters Auditorium, Lower Level
Location: Washington Convention Center
Date: Tue Oct 18
Time: 12:15 PM-01:45 PM
Event Title: Physiologic Lesion Assessment: Complex Anatomy, Difficult Decisions Role: Case Presenter
Room: 149AB
Location: Washington Convention Center
American College of Cardiology meeting, Orlando, March 2009 Date: Wed Oct 19
Time: 03:30 PM-06:00 PM
Event Title: Peripheral Theater - Wednesday
Section Title: LIVE CASE - SESSION VI, Renal and Mesenteric Intervention Role: Live Case Discussant
Room: Peripheral Theater, Lower Level
Location: Washington Convention Center
10
American Heart Association Meeting
Date: Wed Nov. 5
Time: 2:0PM-5:00 PM
Event Title: The role of IVUS in determination of regression of atherosclerosis Role: Moderator
Location: Chicago
American Heart Association Meeting
Date: Tuesday Nov. 5
Event Title: The role of renal physiology in patients with renal artery stenosis Role: Moderator
Location: Orlando
TCT 2007:
Event Title: IVUS and Physiologic Lesion Assessment Workshop: Applications in the DES Era Section Title: Session II: IVUS Pre-intervention Assessment Lecture Title: The Necessity of Assessing Left Main Lesions by IVUS Role: Lecturer
Location: Washington Convention Center
Event Title: IVUS and Physiologic Lesion Assessment Workshop: Applications in the DES Era Section Title: Session IV: The Basics of Physiologic Lesion Assessment Role: Moderator
Location: Washington Convention Center
Event Title: IVUS and Physiologic Lesion Assessment Workshop: Applications in the DES Era Section Title: Session IV: The Basics of Physiologic Lesion Assessment Lecture Title: Audience Q&A
Role: Panel Moderator
Location: Washington Convention Center
Event Title: Peripheral Vascular Intervention: Evaluation and Therapeutic Options Section Title: Section VI: Renal Artery Intervention Lecture Title: Intra-Procedural Assessment Techniques of Renal Stenosis Severity Role: Lecturer
Location: Washington Convention Center
Event Title: Best of Endovascular Interventional Abstracts Section Title: SFA Intervention
Lecture Title: TCT-86: Diagnostic Accuracy of Renal Pressure Measurements to Assess the Significance of Renal Artery Stenosis: Comparison with Intravascular Ultrasound, Quantitative Angiography, and Duplex Ultrasound.
Role: Lecturer
Location: Washington Convention Center
Event Title: Renal Artery Intervention: Unsettled Issues (no Slides!) Section Title: Schedule
Lecture Title: Outcomes of Renal Artery Stenting Based on IVUS and Physiologic Guidance 11
Role: Lecturer
Location: Washington Convention Center
Event Title: Renal Artery Intervention: Unsettled Issues (no Slides!) Section Title: Schedule
Lecture Title: Case Presentation: Treatment of Renal Artery Aneurysms (With Slides) Role: Discussant
Location: Washington Convention Center
Event Title: Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Section Title: Alcohol Septal Ablation: Complex Case Presentations with Panel Discussion Lecture Title: Case 2
Role: Case Presenter
Location: Washington Convention Center
Event Title: IVUS and Physiologic Lesion Assessment Workshop: Applications in the DES Era Section Title: Session II: IVUS Pre-intervention Assessment Lecture Title: The Necessity of Assessing Left Main Lesions by IVUS Role: Lecturer
Location: Washington Convention Center
Event Title: Endovascular Theater
Section Title: Live Case Session IV: Renals
Role: Live Case Discussant
Room: Endovascular Theater, Lower Level
Location: Washington Convention Center
TCT 2008:
Event Title: IVUS, OCT and Physiologic Lesion Assessment: Applications in the DES Era: Fact-Based, Case Review Symposium
Session I: IVUS Assessment Pre-Intervention
Role: Modrator
Event Title: The Absolute Necessity of Assessing Left Main Lesions by IVUS Role: Lecturer
Event Tile: Stump the Panel Case Presentations: Pre-Intervention IVUS Oddities Role: Case discussant
Event title: Prediction of Hypertension Improvement after Renal Artery Stenting: Diagnostic Accuracy of Renal Pressures, Intravascular Ultrasound, and Angiography Role: Lecturer
Event title: The Concept and Technique of Fractional Flow Reserve (With Case Examples) Role: Lecturer
American College of Cardiology Meeting, March 2009: 12
Event Title: Evaluation and treatment of the ambiguous and diseased left main Role: Lecturer
Date: March 28, 2009
Event Title: Diagnostic accuracy of renal pressure gradients in patients with renal artery stenosis Role: Lecturer
Date: March 30, 2009
TCT (Transcatheter Therapy) 2011:
Member of scientific committee of TCT: The role of IVUS and FFR in interventional cardiology American college of Cardiology meeting, 2012
Chair: The role of IVUS in patients with left main coronary artery stenosis TCT 2015:
Event Title: IVUS, OCT and Physiologic Lesion Assessment: Applications in the DES Era: Fact- Based, Case Review Symposium
Session I: IVUS Assessment Pre-Intervention
Role: discussant
Event Title: Left main and bifurcation summit: The role of POT in patients with bifurcation Role: Lecturer
Event Tile: Live case: FFR, OCT IVUS
Role: discussant
Event title:
Event title: The Concept and Technique of Fractional Flow Reserve (With Case Examples) Role: Lecturer
SCAI 2017:
Speaker Protocols and Pathways: Optimizing Operations Managing the Patient Prior to a Procedure: Tips and Tricks 05/12/17 09:20 AM - 09:30 AM Panelists Live Cases - V: New Stent Technologies 05/12/17 01:30 PM - 03:00 PM Moderator All Hands on Deck: Treating Complications 05/12/17 03:00 PM - 04:00 CRT 2018
FFR & iFR Coronary Physiology Workshop - Supported by an educational grant from Philips IGT - D
(12:00 PM – 5:45 PM)
13
CRT 2018
Track: Atherosclerosis, Physiology, Imaging and Research Session: Clinical Outcomes: FFR, iFR, IMR, CFR (1:40 PM – 2:30 PM) Saturday, March 3, 2018
The role of FFR After POT in Patients with Coronary Bifurcation Lesions Role: Speaker
Track: CRT Special Symposium
CRM Journal Reception (Please attend if you can)
Session: CRM Journal Reception (Please attend if you can) (5:00 PM – 6:00 PM) 5:00 PM – 6:00 PM
Room: Gruentzig Theater
Track: Cardiotube Interviews
CardioTube Interviews
Session: CardioTube Interviews (10:15 AM – 10:30 AM) Sunday, March 4, 2018
10:15 AM – 10:30 AM
Room: Omni Shoreham Main Lobby (closest to West Registration) LATE BREAKING TRIAL: Impact Of Crushed Ticagrelor Vs. Eptifibatide Bolus + Clopidogrel On Platelet Reactivity And Periprocedural Myocardial Infarction In Patients With Unstable Angina] Role: Presenter
ACS & AMI Management (8:00 AM – 5:05 PM)
ACS & AMI Management
Session: ACS Pharmacotherapy 2018 (1:10 PM – 3:25 PM) Sunday, March 4, 2018
2:10 PM – 2:20 PM
Room: Empire Ballroom
14
Ticagrelor and Eptifibatide Bolus Versus 2-h Infusion in High-Risk NSTEMI Patients Undergoing Early PCI
Role: Speaker
CRT Special Symposium
CRT Late Breaking Trial Press Conference
Session: CRT Late Breaking Trial Session [Monday Press Conference] (7:00 AM – 8:35 AM) Monday, March 5, 2018
7:00 AM – 7:05 AM
Complex Coronary Interventions I
Session: Late Breaking Trials Session Two (4:20 PM – 5:05 PM) Monday, March 5, 2018
4:35 PM – 4:43 PM
Room: Regency Ballroom
Complex Coronary Bifurcation Workshop (6:45 AM – 8:00 AM) CRT 2018
Track: Coronary
Complex Coronary Bifurcation Workshop
Session: Complex Coronary Bifurcation Workshop (6:45 AM – 8:00 AM) Tuesday, March 6, 2018
7:35 AM – 7:45 AM
Room: Regency Ballroom
The Role of FFR After POT in Patients With Coronary Bifurcation Lesions Your role: Speaker
CRT 2018
Complex Coronary Bifurcation Workshop (6:45 AM – 8:00 AM) 15
Complex Coronary Bifurcation Workshop
Session: Complex Coronary Bifurcation Workshop (6:45 AM – 8:00 AM) Tuesday, March 6, 2018
7:45 AM – 8:00 AM
Room: Regency Ballroom
Panel Discussion: Use of Dedicated Bifurcation Stent System Role: Panel
CBS (coronary bifurcation summit
China, 2018
Venue Session Presentation Title Role Status
1. Nov 30th (Thu) 8:30 am-9: 42 AM Peace Hall, Level 2 CBS2017 How to evaluate complexity of bifurcation lesions :from angiography to intravascular imaging Discussant Yes
2. Nov 30th (Thu) 8:54 am-9:04 am Peace Hall, Level 2 CBS2017 How to evaluate complexity of bifurcation lesions :from angiography to intravascular imaging Case presentation: FIM High-Definition IVUS and FFR-Guided POT on BRS expansion and SB FFR in a coronary Bifurcation Lesion Case Reporter Yes 3. Nov 30th (Thu) 1:00 pm-2: 28 pm Peace Hall, Level 2 CBS2017 Use of dedicated devices in bifurcation lesions
Chair Yes
4. Nov 30th (Thu) 2:30 pm-5:00 pm Jasper Hall, Level 1 CBS 2017 JACC: Cardiovascular intervention symposium and investigator meeting Discussant Yes
5. Dec 1st (Fri) 1:00 PM-2: 35 pm Peace Hall, Level 2 CBS2017 Provisional side branch stenting
Discussant Yes
6. Dec 1st (Fri) 4:56 pm-5:06 pm Peace Hall, Level 2 CBS2017 Vulnerable plaques in bifurcation area
How to recognize carina/plaque shift? Speaker Yes
7. Dec 2nd (Sat) 9:35 am-11: 10 am Peace Hall, Level 2 CBS2017 OCT/IVUS guidance in bifurcation lesions
Discussant Yes
8. Dec 2nd (Sat) 9:47 AM-9: 57 AM, Peace Hall, Level 2 CBS 2017 OCT/IVUS guidance in bifurcation lesions
16
Role of POT guided by IVUS on stent expansion, stent symmetry index, and SB hemodynamics in bifurcation lesions Speaker Yes
TCT 2018
Date: Sat Sep 22
Time: 9:30 AM - 10:30 AM
Event Title: Moderated Poster Session: Intravascular Imaging, PCI, and Long-Term Outcomes I Section Title: Intravascular Imaging, PCI, and Long-Term Outcomes I Role: Moderator
Room: Moderated Posters 7, Exhibit Hall, Ground Level Location: San Diego Convention Center
Date: Sun Sep 23
Time: 9:30 AM - 10:12 AM
Event Title: Didactic Session: Intravascular Imaging - Stent Guidance and Vulnerable Plaque Assessment and Management
Section Title: Session II. Pre-Intervention Lesion Assessment Role: Discussant
Room: Room 2, Upper Level
Location: San Diego Convention Center
Date: Mon Sep 24
Time: 8:30 AM - 9:30 AM
Event Title: Moderated Poster Session: Pharmacology: Dual and Triple Anti-Platelet Therapy I Section Title: Pharmacology: Dual and Triple Anti-Platelet Therapy I Role: Discussant
Room: Moderated Posters 8, Exhibit Hall, Ground Level Location: San Diego Convention Center
Date: Mon Sep 24
Time: 12:18 PM - 12:26 PM
Event Title: Complex Interventions: Expert Case Reviews - Intravascular Imaging – IVUS, OCT and NIRS
Section Title: Intravascular Imaging – IVUS, OCT and NIRS Lecture Title: Case #1: A Case in Which Pre- and Post-interventional IVUS Changed the Number, Length and/or Diameters of Stents Used
Role: Case Presenter
Room: Room 28A-B, Upper Level
17
TCT 2019: San Francesco
Moderator :
The role of vulnerable plaque and therapeutic options Moderator and committee
Challenging cases
Speaker
The role of IVUS in contemporary practice
CRT meeting 2019: Washington DC
Abstract committee
Moderator: Coronary bifurcation lesions: How to protect the side branch Lecture: How to optimize stent expansion
EPIC: Emory
Course-Co-director
Moderator
Coronary bifurcation lesions
Lecture
The role of HD-IVUS in patients undergoing coronary intervention CBS 2019 : coronary bifurcation and left main summit: Nanjing China: Moderator and faculty 1. Nov 28th (Thu) 2:15 pm-3: 15 pm Magnolia Hall, Level 2: Left main & coronary bifurcation summit (CBS2019)
Managing Meeting of Journal of Innovative Interventional Cardiology 2. Nov 29th (Fri) 5:35 pm-5: 45 pm Friendship Hall, Level 2: Left main & coronary bifurcation summit (CBS2019)
Crossfire: Global Challenging Case Presentation
How do you stent the ostial LAD stenosis in patients with STEMI? Speaker Yes 3. Nov 30th (Sat) 9:55 am-12:12 pm, Peace Hall, Level 2: Left main & coronary bifurcation summit (CBS2019)
DAPT in Bifurcation and complex PCI
4. Nov 30th (Sat) 10:31 am-10: 43 am Peace Hall, Level 2: Left main & coronary bifurcation summit (CBS2019)
DAPT in Bifurcation and complex PCI
5. Nov 30th (Sat) 12:30 pm-12: 42 pm: Friendship Hall, Level 2: Complex PCI Left Main and Bifurcation stenting (2)
18
Peer Reviewed Publications
1. Gagnon RF, Leesar M. Development and progression of uremic changes in the mouse model with surgically induced renal failure. Nephron 1990; 54:70-76. 2. Kerin NZ, Ansari-Leesar M, Faitel K, Narala C. The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation. Am Heart J 1993;125:1017-1021.
3. Leesar MA, Martyn R, Talley JD, Frumin H. Non-cardiogenic pulmonary edema complicating acute verapamil overdose. Chest 1994;105:606-607.
4. Stikovac M, Talley JD, Leesar MA. Economic aspects of using alternative diagnostic techniqueas in addition to angiography during percutaneous coronary revascularization. J Interven Cardiol 1994;7:291-296.
5. Leeasr, MA, Joseph SA, Prince CR. Letter to the editor. 1995, NEJM;332:889. 6. Talley JD, Mauldin P, Leeasr MA. A prospective randomized trial of 0.01” versus 0.014” balloon PTCA systems and interventional fellow versus attending physician as a primary operator in elective PTCA. J Interven Cardiol. 1995;8:623-632. 7. Talley JD, Mauldin P, Becker ER, Stikovac M, Leesar MA.. Cost and therapeutic modification of intracoronary ultrasound-assisted coronary angioplasty. Am J Cardiol. 1996;77:1278-1282. 8. Maldonado C, Talley JD, Mayfield-Stokes S, Leesar MA, Shih A, Kalya A. Exogenous Fibronectin to Prevent Neointimal Hyperplasia after Balloon Angioplasty. J Invasive Cardiol. 1996 Mar;8(2):107-112.
9 Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Adenosine preconditions human myocardium during PTCA. Circulation 1997;95:2500-207. 10. Bolli R, Leesar MA. Collateral circulation during coronary angioplasty. J Am Coll Cardiol 1997;29:469-470.
11. Bolli R, Leesar MA. Ischemic preconditioning vs. collateral circulation during coronary angioplasty. Circulation 1998;97:2279.
12. Bolli R, Leesar MA,, Ahmed M, Stoddard M, Broadbent J. Adenosine-induced preconditioning of human myocardium. Circulation 1998; 98:824-825.
13. Leesar MA, Stodard MF, Manchikalapudi S, Bolli R. Bradykinin induced precoditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol. 1999;34:639-50. 14. Mahaffy KW, Puma JA, Barbegalata NA, Dicarli MF, Leesar MA, Bolli R, et.al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of multicenter, randomized, placebo controlled trial (The acute myocardial I nfarction study of adenosine
(AMISTAD) trial. J Am Coll Cardiol, 1999;34:1711-20 15. Makk L.J.K, Leesar MA, Joseph A, Prince C.P., Wright R. Cardioesophageal reflexes:an invasive human study. Digestive Diseases and Sciences 2000;45:2451-4. 19
16. Leesar MA, Stoddard MF, Dawn B, Jasti V, Masden R, Bolli R. Delayed preconditioning – mimetic action of nitroglycerin in patients undergoing PTCA. Circulation: 2001;103:2935-41. 17. Leesar MA, Abdul-Baki T, Akkus NI, Sharma A, Kannan T, Bolli, R. Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina: effects on duration of hospitalization, cost, procedural characteristics, and clinical outcome. J Am Coll Cardiol 2003;41: 1115-1121.
18. Leesar MA. Stoddard MF. Xuan YT. Tang XL. Bolli R. Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. J Am Coll Cardiol 42(3):437-45, 2003.
19. Leesar MA, Abdul-Baki T, Yalamanchili V, Hakim J, Kern M. Conflicting functional assessment of stenoses in patients with previous myocardial infarction. Cath and Cardiovasc Interven 2003:59:489-495.
20. Pasnoori VR, Leesar MA. Use of aminophylline in the treatment of severe symptomatic bradycardia resistant to atropine. Cardiol Rev. 2004;12(2):65-8. 21. Leesar MA, Masden R, Jasti V. Functional assessment of the left main coronary stenosis. Cath and Cardiovasc Interven. 2004 ;62:349-57.
22. Wongpraparut, N, Yalamachili V, Leesar MA. A novel implication of combined stent crushing and intravascular ultrasound for disloged stents. J Inv Cardiol. 2004;16:445-6. 23. Hakim J, Leeasr MA. Quadfurcation of the left main coronary artery: double ramus medianus coronary system. Angiology. 2004;55:109-10.
24. Jasti V, Ivan E, Yalamanchili V, Wongpraparut N, Leesar MA. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation. 2004;110(18):2831-6.
25. Wongpraparut N, Yalamanchili V, Pasnoori V, Satran A, Chandra M, Masden R, Leesar MA. Thirty-Month Outcome after Fractional Flow Reserve-Guided Versus Conventional Multivessel Percutaneous Coronary Intervention. Am J Cardiol 2005;96:877-84. 26. Jenid H, Chandra M, Leesar MA, Bolli R. Delayed preconditiong-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. Circulation 2005;111:2565-71. 27. Thrombolysis and Counterpulsation to Improve Survival in Myocardial Infarction Complicated by Hypotension and Suspected Cardiogenic Shock or Heart Failure: Results of the TACTICS Trial. Ohman E, Nanas J, Stomel RJ, Leesar MA, Nielsen DW, O'dea D, Rogers FJ, Harber D, Hudson MP, Fraulo E, Shaw LK, Lee KL. J Thromb Thrombolysis. 2005;19:33-9. 28. Leesar MA. The use of intravascular ultrasound to determine the significance of the left main coronary stenosis. J Am Coll Cardiol. 2005;46:2145. 20
29. Satran A, Dawn B, MD, Ikram S, MD, Leesar MA. Congenital Ostial Left Main Coronary Artery Stenosis Associated with a Bicuspid Aortic Valve in a Young Woman. J Inv Cardiol. 2006; E114-6.
30. Jenid H, Leesar MA, Bolli R. Cardiac Preconditioning during Percutaneous Coronary Interventions. Card Drug Ther; 2005.
31 Leesar MA Jenid H, Bolli R. Effect of enalaprilat induced precoditioning in patients undergoing coronary angioplasty. JACC 2007 ;49:1607-10.
32. Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar MA. Activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization-- results of the PPAR study. Am Heart J 2007;154(1):137-43. 33. Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E; ANTHEM-TIMI-32 Investigators. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. JACC 2007 ;49:2398-407 34. Elghoul Z, Leesar MA. Iatrogenic fistula between the left anterior descending coronary artery and anterior interventricular vein following stenting. J Invasive Cardiol 2007 Jul;19(7):E188-91. 35. Leesar MA, Mintz GS. Hemodynamic and intravascular ultrasound assessment of an ambiguous left main coronary artery stenosis.Catheter Cardiovasc Interv. 2007;70(5):721-30. 36. Leesar MA. A revisit: repeat stent placement versus angioplasty alone for renal in-stent restenosis. Catheter Cardiovasc Interv. 2008 ;71(5):706-7. 37. Leesar MA. Platelet glycoprotein IIb/IIIa receptor inhibitors: Is there future as bright as in the past? Catheter Cardiovasc Interv. 2008 ;71:907-8
38. Leesar MA. Fractional flow reserve: FFR B4 U stent. Catheter Cardiovasc Interv. 2008
;72:257-8.
39. Leesar MA. Myocardial protection with a beta-blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit. Catheter Cardiovasc Interv. 2008; 72:488-97
40. Flaherty MP, Leesar MA, Dawn B. Acute myocardial infarction in a 19 year-old female owing to hypercoagulable state of pregnancy and the puerperium. J Invasive Cardiol. 2008 ;20: E262 41. Leesar MA. Baseline fractional flow reserve predicts event rates after stenting: A further step but still much to learn. JACC Cardiovasc Interv 2009;2:364-65. 42. Leesar MA. Myocardial protection with a beta-blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit. Catheter Cardiovasc Interv. 2008
;72:498-9
43. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. 21
Fractional flow reserve versus angiography for
Contact this candidate